Center for Innovation [ C4i ]

10-person innovation team in legal ed & policy. Startup Legal Garage; Law & Medicine Initiative; AI & Capital Markets #policy #pharma #drugprices #law

[Professor Robin Feldman @ProfRobnFeldman]

My recent paper with Seton Hall examines three kinds of frequently “obvious” secondary patents, many of which should not be patentable. The results show that all three are associated with significantly extended periods of monopoly protection.

https://t.co/jYnSks2027

[Professor Robin Feldman @ProfRobnFeldman]

“Without the additional patents allowed in our patent system, the U.S. would be seeing generic versions [of GLP-1s] within a year of the rest of the world, instead of waiting many more years”

https://t.co/rYeW0UtHyl

@NBCNews @BerkeleyJr

[Center for Innovation [ C4i ] @C4iUCLaw]

@ProfRobnFeldman's description of the legal space surrounding the OpenAI lawsuit after the Tumbler Ridge shooting, in an interview on @EWTNNewsNightly

[Professor Robin Feldman @ProfRobnFeldman]

"[Legally,] I’d frame it this way: do you want to hold libraries responsible for having books on mass shootings, or for having information books available? If not, then do we think these AI models are more like 'libraries' or more like your Cousin Alfie who drove the getaway car?

[We’ve got to] figure out where they are on that spectrum."

https://t.co/zdyCKew5VN

[UC Law San Francisco @uclaw_sf]

.@ProfRobnFeldman, director of the AI Law & Innovation Institute at UC Law SF, outlined on @KQED and @CBC the key issues in a family’s lawsuit against OpenAI over a February 2026 mass shooting in Tumbler Ridge, British Columbia.

https://t.co/6pCzmZ2w2h

[AI Law and Innovation Institute @AILawInstitute]

Live Recording Tomorrow:

The husband-and-wife team of our own Robin Feldman and her husband Boris Feldman will film a video-podcast discussion about how she used AI to help write her book on AI. Robin will be sharing what she learned from hours of conversation with AI systems.

[Professor Robin Feldman @ProfRobnFeldman]

There has to be a win-win pricing solution for getting Semaglutide to the people who need it. Unfortunately, this solution is unlikely to survive the courts. #pharma

https://t.co/KsQXaieHYi

[UC Law San Francisco @uclaw_sf]

According to #UCLawSF Prof. Robin Feldman, an expert in health care innovation and pharmaceutical law, “Compounding has exploded as its own mini-industry.”

Read more in the Atlantic:
https://t.co/FyskQ2jpj1

[STAT @statnews]

Giving people access to the trailing edge — older but effective products that manufacturers discontinue — offers them more-affordable options. https://t.co/oAQkGakPLv

[UC Law San Francisco @uclaw_sf]

Prof. Robin Feldman spoke w/ Law360 about @uclaw_sf's new AI Law & Innovation Institute housed within @C4iUCLaw, which she directs. The institute's mission is to help courts, lawmakers & regulators adapt to AI as it advances at "quantum speed." https://t.co/UwHSn0vIKY

[Center for Innovation [ C4i ] @C4iUCLaw]

"The point of the obviousness doctrine in patent law is to make sure patents are only granted for the truly innovative [...] If you can get an answer by sticking a query into ChatGPT, that may not be truly innovative.”
--@ProfRobnFeldman

https://t.co/33yFa9gbKQ

[Eleanor Laise @EleanorLaise]

PBM reform takes another step forward in the Senate. @ProfRobnFeldman https://t.co/gTlVTluNiv

[Center for Innovation [ C4i ] @C4iUCLaw]

An article by @ProfRobnFeldman and @marklemley, "Atomistic Antitrust", has won Best Academic Article in the category of "General Antitrust" out of 103 nominated academic articles. https://t.co/fwRasiF1Pp.

[Center for Innovation [ C4i ] @C4iUCLaw]

@ProfRobnFeldman Re: the "enablement standard", it's important that patents "enable" replication of the invention being covered. Patenting a broad genus of molecules, rather than specific inventions, can mean experimentation is still needed...in which case, the patent is overbroad.

[Center for Innovation [ C4i ] @C4iUCLaw]

https://t.co/5B0pH3aEnI
This article covers two interesting cases for patent law. Amgen v. Sanofi involves the enablement standard (see @ProfRobnFeldman's Amicus brief: https://t.co/71FQYe3Z9v) while Gilead would involve the written description requirement.

[Center for Innovation [ C4i ] @C4iUCLaw]

@ProfRobnFeldman: "California’s goal was to get competition into the market however they can manage it [....] If California’s entry results in bringing prices down from other manufacturers, that will be a good thing."

[KFF Health News @KFFHealthNews]

Eli Lilly's news that it plans to cut insulin costs for patients will help, not hinder, the efforts in California and by entrepreneurs to offer lower cost alternatives, drug pricing experts told @besables & @youngsamantha. https://t.co/8bqaS4wyt1

[Center for Innovation [ C4i ] @C4iUCLaw]

Featuring our own @ProfRobnFeldman, a great segment w/ @scrippsnews on product hopping/evergreening in #pharma, adverse PBM incentives, and steps the Inflation Reduction Act takes to mitigate rising prescription drug prices.
#InTheLoop w/ @BryantCP
https://t.co/X4Da4m2oDG

[Professor Robin Feldman @ProfRobnFeldman]

Drug companies use trade secrets to avoid full patent disclosure for biologics like insulin and cancer drugs. You can’t have your cake and eat it. See my article in @columbiastlr: https://t.co/ko1V3FLddz

[Professor Robin Feldman @ProfRobnFeldman]

State attempts to regulate in a host of areas could get a boost or be crippled based on the outcome of #SupremeCourt case National Pork Producers Council et al. v. Karen Ross et al. See my article w/ Gideon Schor in @nyujll, Lochner Revenant. 1/

https://t.co/Vy4kpUp5YN

[Professor Robin Feldman @ProfRobnFeldman]

My interview with Anna Langlois of @GCR_alerts discussing my work on concentration in #pharmaceutical markets, the FTC’s plan to study #PBM concentration, and innovation in pharma, which has suffered after multiple waves of industry consolidation.

https://t.co/Cn3UyUBCNB

[Arnold Ventures @Arnold_Ventures]

Prescription drugs and therapies must be affordable and accessible for patients, employers, and taxpayers. Read about three key ways the drug pricing provisions passed within the #InflationReductionAct will help people.
https://t.co/8Pn13tSb2P